Percentage donor chimerism of clinically engrafting unit after DCB transplantation of MNCs, CD34+ cells, and CD34+ cells + add-back of CD34− cells from the clinically engrafting or the clinically nonengrafting unit in NSG mice (n = 11)*: DCB transplantation with MNCs, but not CD34+ cells, is associated with unit dominance and correlates with patient engraftment, whereas unit dominance is restored with add-back of CD34− to CD34+ DCB from either unit, but engraftment in this setting is dictated by the origin of the CD34− cells
| Experiment no. . | Mouse ID . | Clinically engrafting unit in mice after MNC DCB, % . | Clinically engrafting unit in mice after CD34+ DCB, % . | Clinically engrafting unit in mice after CD34+ DCB + add-back CD34− from engrafting unit, % . | Clinically engrafting unit in mice after CD34+ DCB + add-back CD34− from nonengrafting unit,* % . | Clinically engrafting unit in patient on day 21 after DCB transplantation, % . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| BM . | Spleen . | BM . | Spleen . | BM . | Spleen . | BM . | Spleen . | |||
| 1 | M1 | Not done | Not done | 33 (67) | 36 (64) | 100 (0) | 100 (0) | 0 (100) | 0 (100) | 100 |
| M2 | 29 (71) | 36 (64) | 100 (0) | 100 (0) | 0 (100) | 0 (100) | ||||
| M3 | 29 (71) | 53 (47) | 100 (0) | 100 (0) | Pre | Pre | ||||
| 2 | M1 | Not done | Not done | 23 (77) | 36 (64) | Pre | Pre | 0 (100) | 0 (100) | 100 |
| M2 | 41 (59) | 50 (50) | Pre | Pre | Pre | Pre | ||||
| M3 | Pre | Pre | Pre | Pre | Pre | Pre | ||||
| 3 | M1 | 100 (0) | 100 (0) | 43 (57) | 36 (64) | 100 (0) | 100 (0) | 28 (72) | Inadequate | 100 |
| M2 | 100 (0) | 100 (0) | 46 (54) | 48 (52) | 100 (0) | 100 (0) | 23 (77) | 0 (100) | ||
| M3 | Pre | Pre | Pre | Pre | 100 (0) | 100 (0) | Pre | Pre | ||
| 4 | M1 | 100 (0) | 100 (0) | 86 (14) | 81 (19) | 100 (0) | 100 (0) | 0 (100) | 0 (100) | 100 |
| M2 | 100 (0) | 100 (0) | 62 (38) | 75 (25) | Pre | Pre | 0 (100) | 0 (100) | ||
| M3 | 100 (0) | 100 (0) | Pre | Pre | Pre | Pre | 0 (100) | 0 (100) | ||
| 5 | M1 | 0 (100) | 0 (100) | 100 (0) | 100 (0) | 100 (0) | 100 (0) | 0 (100) | 0 (100) | 100 |
| M2 | 100 (0) | 100 (0) | 100 (0) | 100 (0) | Pre | Pre | 0 (100) | 0 (100) | ||
| M3 | Pre | Pre | 64 (36) | 100 (0) | Pre | Pre | Pre | Pre | ||
| 6 | M1 | 100 (0) | 100 (0) | 86 (14) | 83 (17) | 100 (0) | 100 (0) | 13 (87) | 0 (100) | 100 |
| M2 | Pre | Pre | 93 (7) | 80 (20) | Pre | Pre | 0 (100) | 0 (100) | ||
| M3 | Pre | Pre | 79 (21) | 93 (7) | Pre | Pre | Pre | Pre | ||
| 7 | M1 | 92 (8) | Inadequate | 44 (56) | 39 (61) | Pre | Pre | 33 (67) | 8 (92) | 37 (14) (50% host); blood 100% engrafting unit by day 96 |
| M2 | Pre | Pre | 51 (49) | 43 (57) | Pre | Pre | 50 (50) | 18 (82) | ||
| M3 | Pre | Pre | 42 (58) | 46 (54) | Pre | Pre | 6 (94) | Inadequate | ||
| 8 | M1 | 100 (0) | 100 (0) | 5 (95) | 16 (84) | 100 (0) | 100 (0) | 0 (100) | 0 (100) | 100 |
| M2 | 100 (0) | 100 (0) | 14 (86) | 7 (93) | Pre | Pre | 0 (100) | 0 (100) | ||
| M3 | Pre | Pre | 7 (93) | 10 (90) | Pre | Pre | 0 (100) | 0 (100) | ||
| 9 | M1 | 100 (0) | 100 (0) | 100 (0) | 67 (33) | 100 (0) | 100 (0) | 0 (100) | 0 (100) | 100 |
| M2 | 100 (0) | 100 (0) | 100 (0) | 71 (29) | 100 (0) | 100 (0) | 0 (100) | 0 (100) | ||
| M3 | 100 (0) | 100 (0) | 67 (33) | 73 (27) | 100 (0) | 100 (0) | 0 (100) | 0 (100) | ||
| 10 | M1 | 100 (0) | 100 (0) | 25 (75) | 19 (81) | 100 (0) | 100 (0) | 0 (100) | 0 (100) | 63 (26) (11% host); blood 100% engrafting unit by day 102 |
| M2 | 100 (0) | 100 (0) | 72 (28) | 48 (52) | 100 (0) | 100 (0) | 0 (100) | 0 (100) | ||
| M3 | 100 (0) | 100 (0) | 0 (100) | 33 (67) | 100 (0) | 100 (0) | 0 (100) | 0 (100) | ||
| 11 | M1 | 15 (85) | 29 (71) | 88 (12) | 92 (8) | 83 (17) | 100 (0) | 81 (19) | 17 (83) | 100 |
| M2 | 72 (28) | 71 (29) | Pre | Pre | Pre | Pre | 12 (88) | 0 (100) | ||
| M3 | 90 (10) | 59 (41) | Pre | Pre | Pre | Pre | Pre | Pre | ||
| Experiment no. . | Mouse ID . | Clinically engrafting unit in mice after MNC DCB, % . | Clinically engrafting unit in mice after CD34+ DCB, % . | Clinically engrafting unit in mice after CD34+ DCB + add-back CD34− from engrafting unit, % . | Clinically engrafting unit in mice after CD34+ DCB + add-back CD34− from nonengrafting unit,* % . | Clinically engrafting unit in patient on day 21 after DCB transplantation, % . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| BM . | Spleen . | BM . | Spleen . | BM . | Spleen . | BM . | Spleen . | |||
| 1 | M1 | Not done | Not done | 33 (67) | 36 (64) | 100 (0) | 100 (0) | 0 (100) | 0 (100) | 100 |
| M2 | 29 (71) | 36 (64) | 100 (0) | 100 (0) | 0 (100) | 0 (100) | ||||
| M3 | 29 (71) | 53 (47) | 100 (0) | 100 (0) | Pre | Pre | ||||
| 2 | M1 | Not done | Not done | 23 (77) | 36 (64) | Pre | Pre | 0 (100) | 0 (100) | 100 |
| M2 | 41 (59) | 50 (50) | Pre | Pre | Pre | Pre | ||||
| M3 | Pre | Pre | Pre | Pre | Pre | Pre | ||||
| 3 | M1 | 100 (0) | 100 (0) | 43 (57) | 36 (64) | 100 (0) | 100 (0) | 28 (72) | Inadequate | 100 |
| M2 | 100 (0) | 100 (0) | 46 (54) | 48 (52) | 100 (0) | 100 (0) | 23 (77) | 0 (100) | ||
| M3 | Pre | Pre | Pre | Pre | 100 (0) | 100 (0) | Pre | Pre | ||
| 4 | M1 | 100 (0) | 100 (0) | 86 (14) | 81 (19) | 100 (0) | 100 (0) | 0 (100) | 0 (100) | 100 |
| M2 | 100 (0) | 100 (0) | 62 (38) | 75 (25) | Pre | Pre | 0 (100) | 0 (100) | ||
| M3 | 100 (0) | 100 (0) | Pre | Pre | Pre | Pre | 0 (100) | 0 (100) | ||
| 5 | M1 | 0 (100) | 0 (100) | 100 (0) | 100 (0) | 100 (0) | 100 (0) | 0 (100) | 0 (100) | 100 |
| M2 | 100 (0) | 100 (0) | 100 (0) | 100 (0) | Pre | Pre | 0 (100) | 0 (100) | ||
| M3 | Pre | Pre | 64 (36) | 100 (0) | Pre | Pre | Pre | Pre | ||
| 6 | M1 | 100 (0) | 100 (0) | 86 (14) | 83 (17) | 100 (0) | 100 (0) | 13 (87) | 0 (100) | 100 |
| M2 | Pre | Pre | 93 (7) | 80 (20) | Pre | Pre | 0 (100) | 0 (100) | ||
| M3 | Pre | Pre | 79 (21) | 93 (7) | Pre | Pre | Pre | Pre | ||
| 7 | M1 | 92 (8) | Inadequate | 44 (56) | 39 (61) | Pre | Pre | 33 (67) | 8 (92) | 37 (14) (50% host); blood 100% engrafting unit by day 96 |
| M2 | Pre | Pre | 51 (49) | 43 (57) | Pre | Pre | 50 (50) | 18 (82) | ||
| M3 | Pre | Pre | 42 (58) | 46 (54) | Pre | Pre | 6 (94) | Inadequate | ||
| 8 | M1 | 100 (0) | 100 (0) | 5 (95) | 16 (84) | 100 (0) | 100 (0) | 0 (100) | 0 (100) | 100 |
| M2 | 100 (0) | 100 (0) | 14 (86) | 7 (93) | Pre | Pre | 0 (100) | 0 (100) | ||
| M3 | Pre | Pre | 7 (93) | 10 (90) | Pre | Pre | 0 (100) | 0 (100) | ||
| 9 | M1 | 100 (0) | 100 (0) | 100 (0) | 67 (33) | 100 (0) | 100 (0) | 0 (100) | 0 (100) | 100 |
| M2 | 100 (0) | 100 (0) | 100 (0) | 71 (29) | 100 (0) | 100 (0) | 0 (100) | 0 (100) | ||
| M3 | 100 (0) | 100 (0) | 67 (33) | 73 (27) | 100 (0) | 100 (0) | 0 (100) | 0 (100) | ||
| 10 | M1 | 100 (0) | 100 (0) | 25 (75) | 19 (81) | 100 (0) | 100 (0) | 0 (100) | 0 (100) | 63 (26) (11% host); blood 100% engrafting unit by day 102 |
| M2 | 100 (0) | 100 (0) | 72 (28) | 48 (52) | 100 (0) | 100 (0) | 0 (100) | 0 (100) | ||
| M3 | 100 (0) | 100 (0) | 0 (100) | 33 (67) | 100 (0) | 100 (0) | 0 (100) | 0 (100) | ||
| 11 | M1 | 15 (85) | 29 (71) | 88 (12) | 92 (8) | 83 (17) | 100 (0) | 81 (19) | 17 (83) | 100 |
| M2 | 72 (28) | 71 (29) | Pre | Pre | Pre | Pre | 12 (88) | 0 (100) | ||
| M3 | 90 (10) | 59 (41) | Pre | Pre | Pre | Pre | Pre | Pre | ||
Pre indicates premature mice mortality; and Inadequate, inadequate murine DNA sample.
The murine percentage donor chimerism of the clinically nonengrafting unit is shown in parentheses.